The Trump administration plans to move quickly on its goals to overhaul taxation, healthcare and immigration laws, Vice President-elect Mike Pence said in an interview published by the Wall Street Journal on Friday.
WASHINGTON A senior U.S. Senate Republican warned his party on Thursday against simultaneously overhauling Medicare and the Obamacare health insurance program, saying this would be "biting off more than you can chew."
Now that President-elect Donald Trump has named his pick to oversee the nation's massive healthcare operations, attention turns to who will lead the FDA, with several top U.S. heart doctors expressing strong support for Robert Califf to remain commissioner.
NEW YORK U.S. President-elect Donald Trump chose a former Goldman Sachs banker and a billionaire investor on Tuesday to steer economic policy in his administration and a fierce Obamacare critic to dismantle President Barack Obama's signature healthcare program. | Video
LONDON U.S. healthcare company Johnson & Johnson has raised its offer for Actelion, a source told Reuters on Tuesday, stepping up pressure on the Swiss biotech firm to accept a takeover deal.
Republican U.S. President-elect Donald Trump on Tuesday named a vociferous Obamacare critic and a consultant to help him overhaul the nation's healthcare system.
ZURICH/FRANKFURT U.S. healthcare company Johnson & Johnson said on Friday it was in preliminary talks with Actelion about a potential takeover of Europe's largest biotech firm, currently valued at about $20 billion.
U.S. healthcare company Johnson & Johnson has approached Swiss biotechnology firm Actelion Ltd about a potential takeover, Bloomberg reported on Thursday, citing people it said were familiar with the matter.
Ascend Learning LLC, a U.S. maker of educational software used in sectors such as healthcare, is exploring a sale that it hopes will value the company at more than $2 billion, including debt, according to people familiar with the matter.
Mylan NV has declined a U.S. Senate committee request to testify about a $465 million pending settlement to resolve charges the company underpaid government healthcare programs by misclassifying its the EpiPen emergency allergy treatment.
Prosecutors demanded details from Valeant Pharmaceuticals on its patient assistance programs, drug pricing and distribution practices. Full Article